English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of this phase II clinical trial (NCT02965001) was to evaluate the prognostic value of urokinase-type plasminogen activator receptor (uPAR) PET/CT with the novel ligand 68 Ga-NOTA-AE105 in head and neck cancer and compare it with 18 F-FDG. Methods: Patients with head and neck squamous cell carcinoma referred for curatively intended radiotherapy were eligible and prospectively included in this study. 68 Ga-uPAR and 18 F-FDG PET/CT were performed before initiation of curatively intended radiotherapy, and the SUV max of the primary tumor was measured on both PET/CT studies by 2 independent readers. Relapse-free survival (RFS) and overall survival (OS) were calculated, and optimal cutoffs were established for 68 Ga-uPAR and 18 F-FDG PET independently and compared using log rank and Kaplan-Meier statistics, as well as univariate and multivariate analysis in a Cox proportional-hazards model. Results: In total, 57 patients were included and followed for a median of 33.8 mo (range, 2.30-47.2, mo). The median SUV max of the primary tumors was 2.98 (range, 1.94-5.24) for 68 Ga-uPAR and 15.7 (range, 4.24-45.5) for 18 F-FDG. The optimal cutoffs for 68 Ga-NOTA-AE105 SUV max in the primary tumor were 2.63 for RFS and 2.66 for OS. A high uptake of 68 Ga-NOTA-AE105 (SUV max above cutoff) was significantly associated with poor RFS and OS (log-rank P  = 0.012 and P  = 0.022). 68 Ga-NOTA-AE105 uptake in the primary tumor was significantly associated with poor RFS in univariate analysis (hazard ratio [HR], 8.53 [95% CI, 1.12-64.7]; P  = 0.038), and borderline-associated with OS (HR, 7.44 [95% CI, 0.98-56.4]; P  = 0.052). For 18 F-FDG PET, the optimal cutoffs were 22.7 for RFS and 22.9 for OS. An 18 F-FDG SUV max above the cutoff was significantly associated with reduced RFS (log-rank P  = 0.012) and OS (log-rank P  = 0.000). 18 F-FDG uptake was significantly associated with reduced RFS (HR, 3.27 [95% CI, 1.237-8.66]; P  = 0.017) and OS (HR, 7.10 [95% CI, 2.60-19.4]; P  &lt; 0.001) in univariate analysis. In a multivariate analysis including 68 Ga-uPAR SUV max , 18 F-FDG SUV max , TNM stage, and p16 status, only 68 Ga-uPAR SUV max remained significant (HR, 8.51 [95% CI, 1.08-66.9]; P  = 0.042) for RFS. For OS, only TNM stage and 18 F-FDG remained significant. Conclusion: The current trial showed promising results for the use of 68 Ga-uPAR PET SUV max in the primary tumor to predict RFS in head and neck squamous cell carcinoma patients referred for curatively intended radiotherapy when compared with 18 F-FDG PET, TNM stage, and p16 status. 68 Ga-uPAR PET could potentially become valuable for identification of patients suited for deescalation of treatment and risk-stratified follow-up schemes.

the journal of nuclear medicine

Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with <sup>18</sup>F-FDG PET/CT: A Single-Center Prospective Study

Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with 18F-FDG PET/CT: A Single-Center Prospective Study

Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with ¹⁸F-FDG PET/CT: A Single-Center Prospective Study